Quantitative susceptibility mapping versus R2* for iron tracking
Clinical Research & Biomarkers

Quantitative susceptibility mapping versus R2* for iron tracking

When a translational team designs a longitudinal trial to track iron-modifying therapy in neurodegeneration, the central methodological decision is rarely the drug — it is the biomarker.

September 22, 2026 · 11 min read

Fresh in the feed

About

Bridging neuroimaging software and clinical practice.